XERIS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.48 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 197.98K shares.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.29M shares.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month |
|---|---|---|
| 2026-06-30 | 197.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.48M shares 10-Q · filed 2026-08-06 |
| 2026-03-31 | 2.29M shares 10-Q · filed 2026-05-07 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |